How Much Does Actos (Pioglitazone) Cost in Oregon in 2026?

Oregon Cash Prices for Generic Pioglitazone

The average cash price for a 30-day supply of generic pioglitazone at Oregon retail pharmacies sits at roughly $15 in 2026. This makes pioglitazone one of the least expensive branded-to-generic diabetes medications on the market, falling well below drugs like brand-name SGLT2 inhibitors or GLP-1 receptor agonists that can exceed $900 per month without insurance.

Prices vary across pharmacy chains. Costco and Walmart pharmacies in Portland and Eugene tend to price a 30-day supply of pioglitazone 30 mg between $8 and $12. Independent pharmacies may charge $18 to $25. Fred Meyer and Safeway pharmacies, both common across Oregon, generally fall in the $12 to $17 range. These figures reflect uninsured cash-pay transactions and do not account for coupon or discount card savings.

Brand-name Actos, manufactured by Takeda, carries a list price of approximately $60 per month. Few patients fill the brand product when generic pioglitazone is bioequivalent and costs a fraction of the price. The FDA Orange Book rates the generic as therapeutically equivalent (AB-rated) to Actos.

For patients paying entirely out of pocket, GoodRx and RxSaver coupons can bring the price to $4 to $8 at select Oregon pharmacies. Mark Cuban's Cost Plus Drugs lists pioglitazone 30 mg at a similarly low markup, though shipping adds $5. Pioglitazone's generic competition is mature enough that these discount tools have a narrower margin of savings than they do on newer molecules.

Oregon Medicaid (OHP) Coverage

Oregon Health Plan (OHP) covers pioglitazone for its FDA-approved indication of type 2 diabetes mellitus, subject to prior authorization. The PA requirement is standard across Oregon's coordinated care organizations (CCOs) and applies to both brand Actos and the generic.

Prior authorization criteria typically require documentation that the patient has tried or is currently using metformin (or has a documented contraindication such as an eGFR below 30 mL/min/1.73 m²) and that an A1c remains above the treatment target. Oregon's Pharmacy and Therapeutics Committee has kept thiazolidinediones on the preferred drug list with PA since 2019, balancing cost-effectiveness against alternatives like sulfonylureas and SGLT2 inhibitors.

Copays under OHP are minimal. Most fee-for-service Medicaid beneficiaries in Oregon pay $1 to $3 per generic prescription. Some CCOs waive copays entirely for diabetes medications. The Oregon Health Authority publishes its Practitioner-Managed Prescription Drug Plan formulary updates quarterly, and pioglitazone has retained preferred status through Q2 2026.

Off-label use of pioglitazone for nonalcoholic steatohepatitis (NASH), now reclassified as metabolic dysfunction-associated steatohepatitis (MASH), is not automatically covered under OHP. Prescribers seeking Medicaid coverage for this indication must submit a medical exception request with supporting evidence. The PIVENS trial (N=247) demonstrated that pioglitazone 30 mg significantly improved histological features of NASH compared to placebo over 96 weeks, and this study is frequently cited in exception requests. The American Association for the Study of Liver Diseases (AASLD) practice guidance lists pioglitazone as a pharmacotherapy option for biopsy-proven NASH in patients with or without type 2 diabetes.

Commercial Insurance in Oregon

Most commercial plans available through the Oregon Health Insurance Marketplace and employer-sponsored coverage place generic pioglitazone on Tier 1 (preferred generic). Copays at Tier 1 range from $0 to $15 depending on the plan.

Providence Health Plan, the largest commercial insurer in Oregon by enrollment, lists pioglitazone on its preferred generic tier with a $10 copay for most individual and small-group plans. Regence BlueCross BlueShield of Oregon similarly classifies pioglitazone as Tier 1, with copays between $5 and $12. Moda Health, PacificSource, and Kaiser Permanente Northwest all cover generic pioglitazone without prior authorization for the type 2 diabetes indication.

Brand Actos faces a different situation. Insurers either do not cover the brand when a generic is available (mandatory generic substitution) or place it on a non-preferred brand tier with copays exceeding $40. Oregon state law (ORS 689.515) permits pharmacists to substitute an AB-rated generic unless the prescriber writes "brand medically necessary" on the prescription, so the vast majority of Actos prescriptions in Oregon are dispensed as generic pioglitazone.

For patients on high-deductible health plans (HDHPs), pioglitazone qualifies as a preventive drug for diabetes management under IRS Notice 2019-45. This means some HDHPs cover pioglitazone before the deductible is met, though plan-level variation exists. Patients should verify with their specific insurer.

Takeda Savings Programs and Manufacturer Assistance

Takeda, the manufacturer of brand Actos, previously operated a savings card program that reduced copays for commercially insured patients. That program has been discontinued for Actos as the drug has been fully genericized. No active Takeda copay card exists for Actos in 2026.

However, Takeda's patient assistance program (Takeda Help at Hand) may still provide brand Actos at no cost to uninsured patients meeting income eligibility criteria, generally household income at or below 250% of the federal poverty level. Applications require proof of income and a prescription from a licensed provider.

Generic manufacturers do not typically offer savings cards for pioglitazone because the cash price is already low. The most practical savings route for uninsured Oregon patients remains pharmacy discount cards (GoodRx, SingleCare, RxAssist) or the $4 generic lists at Walmart and Costco, where pioglitazone 15 mg and 30 mg have appeared consistently since 2013.

Oregon also participates in the 340B Drug Pricing Program, which allows qualifying safety-net clinics and hospitals (including many FQHCs across the state) to purchase pioglitazone at deeply discounted rates. Patients who receive care at 340B-eligible sites in Portland (e.g., OHSU, Central City Concern), Salem, Bend, or Medford may access pioglitazone at reduced or zero cost through these programs.

Compounded Pioglitazone in Oregon

Compounded pioglitazone is available through licensed 503A compounding pharmacies in Oregon. Under federal and Oregon state pharmacy law, a 503A pharmacy can compound pioglitazone pursuant to a valid patient-specific prescription when a clinical need exists that commercially available products do not meet. Examples include patients who need a dose not commercially available (e.g., 7.5 mg), those who cannot swallow tablets and need a liquid suspension, or patients with allergies to inactive ingredients in the commercial product.

Oregon Board of Pharmacy regulations (OAR 855-045) govern 503A compounding within the state. Compounded pioglitazone is not a substitute for the commercially available generic when the FDA-approved product meets the patient's needs. The distinction matters because compounded drugs do not undergo FDA approval for safety and efficacy, a point the FDA has repeatedly emphasized.

Cost for compounded pioglitazone varies. Some 503A pharmacies in Oregon price compounded oral suspensions between $20 and $40 for a 30-day supply, while others bundle compounding fees into subscription telehealth models at no separate medication cost. Insurance rarely covers compounded medications, so patients typically pay out of pocket.

Outsourcing facilities (503B) can also produce pioglitazone, though 503B-compounded pioglitazone is less commonly encountered because the commercial generic supply is stable and inexpensive. No current shortage of pioglitazone has been reported on the FDA Drug Shortage Database.

Telehealth Prescribing in Oregon

Oregon permits telehealth prescribing of pioglitazone. The Oregon Medical Board allows licensed physicians and nurse practitioners to prescribe non-controlled substances, including pioglitazone, after a synchronous audio-visual visit or, in some circumstances, an asynchronous (store-and-forward) encounter.

Telehealth platforms operating in Oregon can prescribe pioglitazone for both its FDA-approved indication (type 2 diabetes) and off-label uses (such as NASH/MASH) provided the prescriber exercises appropriate clinical judgment and documents the rationale. Oregon's telehealth parity law (ORS 743A.058) requires commercial insurers to cover telehealth visits at the same rate as in-person visits, meaning the prescribing visit itself should not carry additional patient cost.

For patients in rural Oregon counties (Harney, Grant, Wheeler, Lake, and others with limited endocrinology access), telehealth may be the most practical path to a pioglitazone prescription. The Oregon Office of Rural Health reports that 26 of Oregon's 36 counties have no practicing endocrinologist, making remote diabetes management a practical necessity, not a convenience.

A1c and fasting glucose labs, required for pioglitazone initiation and monitoring, can be drawn at any Quest Diagnostics or Labcorp location in Oregon or at local hospital labs. Baseline liver function tests (ALT, AST) are recommended before starting pioglitazone per the FDA-approved prescribing information, given the class history with troglitazone hepatotoxicity (pioglitazone itself has not been associated with clinically significant liver injury in post-marketing surveillance).

Clinical Value Context: Why Pioglitazone Remains Relevant

Pioglitazone's low cost is paired with a clinical evidence base that extends beyond glycemic control. The PROactive trial (N=5,238) showed that pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16% (HR 0.84, 95% CI 0.72 to 0.98, P=0.027) in patients with type 2 diabetes and macrovascular disease over a mean 34.5 months of follow-up. This cardiovascular signal, confirmed in subsequent meta-analyses, positions pioglitazone as a cost-effective option for patients who need both glucose lowering and cardiovascular risk reduction.

The IRIS trial (N=3,876) extended pioglitazone's relevance to patients without diabetes. In insulin-resistant patients with a recent ischemic stroke or TIA, pioglitazone 45 mg reduced the risk of stroke or MI by 24% compared to placebo (HR 0.76, 95% CI 0.62 to 0.93, P=0.007) over 4.8 years.

"Pioglitazone is one of the most underutilized medications in cardiometabolic medicine, given its cardiovascular benefits and current generic pricing," noted the American Diabetes Association's 2024 Standards of Care, which lists pioglitazone as a recommended option for patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

For NASH/MASH, the PIVENS trial showed that pioglitazone 30 mg improved the composite histological endpoint (reduction in NAS score by 2 or more points with no worsening of fibrosis) in 34% of pioglitazone-treated patients versus 19% of placebo-treated patients (P=0.04). The AASLD practice guidance from 2023 recommends pioglitazone for patients with biopsy-proven NASH regardless of diabetes status, rating the evidence as Grade B.

Weight gain (mean 2.5 to 4.7 kg over 6 to 12 months) and fluid retention are the most common reasons clinicians hesitate to prescribe pioglitazone. The fluid retention risk makes it contraindicated in NYHA Class III or IV heart failure. An FDA safety review from 2016 also noted a modestly increased risk of bladder cancer (incidence rate 0.06% per year for pioglitazone vs. 0.04% for comparators), a signal that remains under ongoing pharmacovigilance but has not led to market withdrawal.

Price Comparison: Pioglitazone vs. Alternatives in Oregon

To put pioglitazone's Oregon cost in perspective, consider the monthly cash-pay prices (approximate, 2026) of other diabetes medications available in Oregon:

Metformin 1000 mg twice daily runs about $4 to $8 at most Oregon pharmacies. Glipizide 10 mg twice daily costs $4 to $10. Pioglitazone 30 mg once daily averages $15. Empagliflozin (Jardiance) 25 mg once daily costs $550 to $620 without insurance. Semaglutide (Ozempic) 1 mg weekly injection runs $900 to $1,100 without insurance. Tirzepatide (Mounjaro) 5 mg weekly injection costs $1,000 to $1,200 without insurance.

For uninsured patients in Oregon who need add-on therapy to metformin with cardiovascular benefit, pioglitazone at $15 per month represents a fraction of the cost of SGLT2 inhibitors or GLP-1 receptor agonists. The ADA Standards of Care recommend choosing among these classes based on patient-specific factors including cost, comorbidities, and side-effect profile. In Oregon, where approximately 6.8% of the population is uninsured according to 2024 Census Bureau data, pioglitazone's generic pricing is a meaningful factor in treatment access.

How to Get the Lowest Price in Oregon

Patients in Oregon looking to minimize out-of-pocket cost for pioglitazone should follow a specific sequence. First, check whether your insurance plan covers pioglitazone at Tier 1 (most do). If uninsured, compare cash prices at Costco, Walmart, and Fred Meyer, all of which tend to offer pioglitazone under $12. Apply a GoodRx or SingleCare coupon at checkout. If you receive care at a federally qualified health center or 340B-eligible clinic, ask whether you qualify for 340B drug pricing. For OHP (Medicaid) beneficiaries, ensure your prescriber submits the prior authorization; approval rates for pioglitazone PA requests in Oregon exceed 85% when step-therapy criteria are documented.

The Oregon Prescription Drug Program (OPDP), a state-sponsored discount program open to all Oregon residents regardless of insurance status, also covers pioglitazone. OPDP enrollment is free, and the program negotiates supplemental rebates that can reduce costs at participating pharmacies. Details are available through the Oregon Health Authority.

Patients who fill a 90-day supply rather than 30-day supply often receive a per-unit discount of 10% to 20% at Oregon pharmacies. Mail-order pharmacies (Express Scripts, CVS Caremark, Optum Rx) offer 90-day generic pioglitazone for $10 to $25, depending on the plan.